Pfizer Inc. $PFE Holdings Decreased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 11.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 514,459 shares of the biopharmaceutical company’s stock after selling 64,703 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Pfizer were worth $12,388,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the fourth quarter worth approximately $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer in the second quarter valued at approximately $26,000. Field & Main Bank bought a new position in shares of Pfizer during the 2nd quarter worth about $27,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. raised its stake in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $29.02 on Thursday. The stock has a market cap of $165.42 billion, a P/E ratio of 38.19, a PEG ratio of 1.92 and a beta of 0.34. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $29.09. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a 50 day simple moving average of $25.79 and a 200 day simple moving average of $26.32.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business posted $0.78 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date was Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. BMO Capital Markets lowered their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, UBS Group restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly performance: Pfizer reported earnings and revenue above expectations, with quarterly revenue increasing year over year. The results, along with growth in vaccines and oncology, have helped drive renewed investor interest. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Legal overhang reduced: Pfizer’s reported settlement of more than 6,000 Depo-Provera lawsuits removes some litigation uncertainty and may be viewed favorably by investors. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Pipeline activity: Pfizer has begun a Phase 1 study of asthma candidate PF-08103402. Although early-stage programs are not near-term revenue drivers, the trial provides another potential growth asset as the company works to offset future patent expirations. Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1
• Neutral Sentiment: Valuation and dividend appeal: A bullish investment case argues that PFE remains attractive below $30 for patient, income-oriented investors, supported by its dividend and long-term recovery potential. Should You Buy Pfizer Stock Below $30?
• Negative Sentiment: Growth concerns persist: Commentary highlights declining core-business revenue and the approaching patent cliff. Pfizer’s AI strategy is viewed as a longer-term promise rather than evidence of immediate earnings growth. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
• Negative Sentiment: Bearish sentiment remains visible: Jim Cramer declined to recommend Pfizer despite its dividend, while unusually high put-option activity suggests some traders are positioning for downside or hedging near the recent high. Cramer Won’t Recommend Pfizer Even With Its Dividend

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.